FY2024 EPS Estimates for PolyPid Decreased by HC Wainwright

PolyPid Ltd. (NASDAQ:PYPD) – Equities researchers at HC Wainwright cut their FY2024 earnings per share estimates for shares of PolyPid in a report issued on Monday, December 16th. HC Wainwright analyst R. Selvaraju now expects that the company will earn ($4.83) per share for the year, down from their prior estimate of ($4.39). HC Wainwright has a “Buy” rating and a $14.00 price target on the stock. The consensus estimate for PolyPid’s current full-year earnings is ($4.39) per share. HC Wainwright also issued estimates for PolyPid’s Q4 2024 earnings at ($1.05) EPS, Q1 2025 earnings at ($0.86) EPS, Q2 2025 earnings at ($0.71) EPS, Q3 2025 earnings at ($0.57) EPS, Q4 2025 earnings at ($0.40) EPS and FY2025 earnings at ($2.41) EPS.

Separately, Craig Hallum started coverage on shares of PolyPid in a report on Monday, November 4th. They set a “buy” rating and a $10.00 target price on the stock.

PolyPid Price Performance

Shares of PolyPid stock traded up $0.37 on Thursday, reaching $2.87. The stock had a trading volume of 19,086 shares, compared to its average volume of 8,255. The business’s 50 day moving average is $3.29 and its two-hundred day moving average is $3.57. The company has a market cap of $13.77 million, a P/E ratio of -0.37 and a beta of 1.33. PolyPid has a 1 year low of $2.37 and a 1 year high of $9.20. The company has a current ratio of 1.00, a quick ratio of 1.00 and a debt-to-equity ratio of 1.17.

Institutional Trading of PolyPid

An institutional investor recently bought a new position in PolyPid stock. Stonepine Capital Management LLC bought a new stake in shares of PolyPid Ltd. (NASDAQ:PYPD) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 138,504 shares of the company’s stock, valued at approximately $476,000. Stonepine Capital Management LLC owned about 2.89% of PolyPid as of its most recent filing with the Securities and Exchange Commission. 26.47% of the stock is currently owned by hedge funds and other institutional investors.

PolyPid Company Profile

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.